Please login to the form below

Not currently logged in
Email:
Password:

Sanofi-aventis and John Hopkins Uni unite for allergy research

Sanofi-aventis has announced that it has teamed up with the Division of Allergy and Clinical Immunology at the John Hopkins University School of Medicine, Maryland under a three-year deal

Sanofi-aventis has announced that it has teamed up with the Division of Allergy and Clinical Immunology (ACI) at the John Hopkins University School of Medicine, Maryland under a three-year deal.

The partnership will undertake to develop new ways of treating respiratory diseases such as severe asthma and chronic obstructive pulmonary disease (COPD), along with immuno-allergic diseases.

For each research project, the two organisations will work on identifying new therapies, and will jointly design potential clinical studies and select biomarkers.

"This collaboration will allow sanofi-aventis and John Hopkins ACI to join their efforts to identify new therapeutic approaches, in particular in severe asthma and COPD," said Dr Marc Cluzel, senior vice president of research and development at sanofi-aventis.

Traditional treatment methods such as high dose inhaled steroids are not effective in all severe asthma sufferers. A better understanding of the effect the disease has on the functions of various cells in the body is needed in order to develop innovative therapies for these patients.

17th July 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Frontera Group

Welcome to Frontera Group where our agencies immerse you into the world of the patient....

Latest intelligence

Where next in Alzheimer’s disease R&D?
How past failures and emerging biology are reshaping drug development...
Brain scan
Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...
Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...

Infographics